According to previous results achieved in our laboratory, we found that the widely used therapeutics, such as LBH589 (Panobinostat), a potent and broad spectrum of HDACi, Bortezomib (Velcade), a proteasome inhibitor, and Lenalidomide (Revlimid), an immunomodulatory drug, increased GLS1 protein in tumor lines. This evidence concerns the gene GLS and neoplasm.